Thromb Haemost 1999; 81(01): 161-162
DOI: 10.1055/s-0037-1614435
Letters to the Editor
Schattauer GmbH

The Prevalence of the Prothrombin 20210 G →A Mutation Is not Increased in Angiographically Confirmed Coronary Artery Disease

W. Prohaska
1   From the Herz- und Diabeteszentrum NRW, Universitätsklinik der Ruhr-Universität Bochum, Institut für Laboratoriumsund Transfusionsmedizin und Kardiologische Klinik, Bad Oeynhausen, Germany
,
M. Schmidt
1   From the Herz- und Diabeteszentrum NRW, Universitätsklinik der Ruhr-Universität Bochum, Institut für Laboratoriumsund Transfusionsmedizin und Kardiologische Klinik, Bad Oeynhausen, Germany
,
H. Mannebach
1   From the Herz- und Diabeteszentrum NRW, Universitätsklinik der Ruhr-Universität Bochum, Institut für Laboratoriumsund Transfusionsmedizin und Kardiologische Klinik, Bad Oeynhausen, Germany
,
U. Gleichmann
1   From the Herz- und Diabeteszentrum NRW, Universitätsklinik der Ruhr-Universität Bochum, Institut für Laboratoriumsund Transfusionsmedizin und Kardiologische Klinik, Bad Oeynhausen, Germany
,
K. Kleesiek
1   From the Herz- und Diabeteszentrum NRW, Universitätsklinik der Ruhr-Universität Bochum, Institut für Laboratoriumsund Transfusionsmedizin und Kardiologische Klinik, Bad Oeynhausen, Germany
› Author Affiliations
Further Information

Publication History

Received28 August 1998

Accepted after revision24 September 1998

Publication Date:
08 December 2017 (online)

 

 
  • References

  • 1 van der Meer FJM, Koster T, Vandenbroucke E, Briet E, Rosendaal FR. The Leiden Thrombophilia Study. Thromb Haemost 1997; 78: 631-5.
  • 2 Ridker PM, Hennekens ChH, Lindpaintner K, Stampfer MJ, Eisenberg PR, Miletich JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 1995; 332: 912-7.
  • 3 Prohaska W, Mannebach H, Schmidt M, Gleichmann U, Kleesiek K. Evidence against heterozygous coagulation factor V 1961 G to A mutation with resistance to activated protein C being a risk factor for coronary artery disease and myocardial infarction. J Mol Med 1995; 73: 521-4.
  • 4 Rosendaal FR, Siscovick DS, Schwartz SM, Beverly RK, Psaty BM, Longstreth Jr WT, Raghunathan TE, Koepsell TD, Reitsma PH. Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women. Blood 1997; 89: 2750
  • 5 Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3’-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88: 3698-703.
  • 6 Nachman RL. Thrombosis and atherogenesis: Molecular connections. Blood 1992; 79: 1897-906.
  • 7 Ferraresi P, Marchetti G, Legnani C, Cavallari E, Castoldi F, Mascoli F, Ardissino D, Palareti G, Bernardi F. The heterozygous 20210 G/A pro-thrombin genotype is associated with early venous thrombosis in inherited thrombophilias and is not increased in frequency in artery disease. Arterioscler Thromb Vasc Biol 1997; 17: 2418-22.
  • 8 Rosendaal FR, Siscovick DS, Schwartz SM, Psaty BM, Raghunathan TE, Vos HL. A common prothrombin variant (20210 G to A) increases the risk of myocardial infarction in young women. Blood 1997; 90: 1747-50.